Navigation Links
EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study

Results Demonstrate Activity in Advanced Disease

ROCKVILLE, Md., Oct. 24 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of results for its Phase 2, open-label study for Panzem(R) NCD (2ME2 or 2-methoxyestradiol) in patients with ovarian cancer. The results were presented by Dr. Daniela Matei, principal investigator for the study representing the Hoosier Oncology Group, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held this week in San Francisco, California.

(Logo: )

Data from the Phase 2 study demonstrate that Panzem(R) NCD, administered as a single agent in patients with platinum refractory epithelial ovarian cancer, resulted in one patient with a confirmed partial response of their CA- 125. Five patients, out of the 18 patients enrolled, achieved stable disease lasting greater than three months. Panzem(R) NCD was well tolerated and no significant neuropathy, myelosuppression or thromboembolic side effects were reported. Three patients remained on study for more than 6 months and two of these patients are still on study.

Data from in vitro studies demonstrated that 2ME2 has activity against a variety of ovarian carcinoma cell lines including those resistant to other chemotherapeutic agents. In preclinical models of ovarian cancer, 2ME2 has shown a significant survival advantage compared to animals that did not receive treatment. Furthermore, in a Phase 1 clinical study conducted by the National Cancer Institute with Panzem(R) Capsules, an ovarian cancer patient with the clear cell subtype experienced a durable partial response to 2ME2 lasting over three years after failing three prior chemotherapy regimens.

Carolyn F. Sidor, M.D., EntreMed Vice President and Chief Medical Officer commented on the study, "Results from this study continue to demonstrate that Panzem(R) NCD has modest activity and an excellent safety profile as a single agent in heavily pretreated and refractory ovarian cancer patients. The stage is now set for us to consider additional trials where Panzem(R) NCD can be combined with approved agents in an attempt to provide clinical benefit to patients with advanced cancers."

To view the poster presentation, visit the Company's web site at

About Ovarian Cancer

Ovarian cancer accounts for 4% of all cancers among women in the United States, and ranks fifth as the cause of cancer deaths. The American Cancer Society estimates that there will be approximately 22,000 newly diagnosed cases of ovarian cancer in the U.S. in 2007 resulting in approximately 15,000 deaths. About half of all ovarian cancers occur in post-menopausal women. Ovarian cancer is frequently asymptomatic in the early stages. As a result, ovarian cancer is often not diagnosed until stage III or IV, where 5-year survival rates decline to 10-20%. Current drug therapy involves paclitaxel and carboplatin/cisplatin regimens. Many patients develop resistance to these drugs, so there is substantial need for innovative therapies that can overcome resistance, either as a single agent or in combination with cytotoxic agents.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) NCD (2-methoxyestradiol or 2ME2) is currently in multiple Phase 2 clinical trials for cancer. MKC-1, an oral cell-cycle regulator, is in multiple Phase 1 and 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. Panzem(R) is also in preclinical development for rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, is in preclinical development for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).


Ginny Dunn

Associate Director, Corporate Communications & Investor Relations

EntreMed, Inc.


SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
2. IDM Pharma Presents Preliminary Results of Melanoma Vaccine Clinical Trial
3. Living Liver Donor Who Saved Life of Mother-in-law Represents Cedars-Sinai in Rose Parade
4. Childrens Hospital Boston Presents at the Society for Adolescent Medicine Annual Meeting
5. Monogram Presents Results of First ETag Breast Cancer Studies
6. Novagali Pharma Presents Phase III Clinical Trial of Vekacia(R) for Vernal Keratoconjunctivitis
7. Experimental treatment for Ebola Virus Shows promising results in mice
8. Hormone Deficiency Results In Miscarriage
9. Gleevec gets hopeful results
10. Breast Implants May Interfere With The Interpretation Of Mammogram Results
11. DNA Testing For More Accurate Results
Post Your Comments:
(Date:11/30/2015)... NC (PRWEB) , ... November 30, 2015 , ... ... practices in 2016. In 2016, expected coding changes are likely to include new ... service codes. It’s not easy to understand the effects of code changes in ...
(Date:11/29/2015)... ... November 30, 2015 , ... ... new company, Sublime Beauty NATURALS®. All products are available on Amazon or its ... oils, organic facial serums and USDA Certified Organic Sesame Oil for Oil Pulling," ...
(Date:11/29/2015)... (PRWEB) , ... November 29, 2015 , ... NewsWatch featured ... technology products available to consumers. Amanda Forstrom, a technology expert and special reporter for ... be a reality in the future. , It’s the future because flying cars are ...
(Date:11/29/2015)... CA (PRWEB) , ... November 29, 2015 , ... ... all new and unique analog distortion effect tool designed specially for Final Cut ... footage, and create limiltess looks with the easy-to-use modification controls. Destoying and creating ...
(Date:11/28/2015)... ... 28, 2015 , ... Safe storage for contraceptive devices may not always be ... New Jersey and the other from Bradley Beach, New Jersey, there is an easy ... of having to replace NuvaRings more often than necessary. As such, it affords peace ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)... Iowa , Nov. 29, 2015 ... ultrasound guidance technology at the Radiological Society of ... in Chicago November 29 ... system is designed to offer customers unrivaled versatility, ... --> ...
(Date:11/27/2015)... YORK , November 27, 2015 ... system is set to go online. The potential to ... processes is vast and far from fully exploited as ... to patient health records, either via mobile tablet or ... ) --> ) --> ...
(Date:11/27/2015)... Research and Markets ( ) has ... Market 2015-2019" report to their offering. ... report, the author the present scenario and growth prospects ... calculate the market size, the report considers revenue generated ... IUDs and copper IUDs. The report forecasts the global ...
Breaking Medicine Technology: